Page 4 - Amivantamab Rybrevant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Amivantamab rybrevant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Amivantamab Rybrevant Today - Breaking & Trending Today

Amivantamab Plus Lazertinib Improved PFS for EGFR-Mutated Advanced NSCLC

MARIPOSA demonstrated the combination reduced risk of progression or death by 30% compared with osimertinib. MARIPOSA-2 found amivantamab plus chemotherapy and amivantamab plus chemotherapy and lazertinib also improved progression-free survival (PFS) over chemotherapy after progression on osimertinib. ....

United States , Soult Ukpyolsi , South Korea , Republic Of Korea , Antonio Passaro , Byoung Chul Cho , Zofia Piotrowska , Yonsei University College Of Medicine , Harvard Medical School , European Institute Of Oncology , Yonsei Cancer Center , Division Of Thoracic Oncology , Harvard Medical School Zofia Piotrowska , Yonsei University College , Thoracic Oncology , European Institute , Massachusetts General Hospital , Esmo Congress ,

Dr Girard on the Efficacy of First-Line Amivantamab Plus Chemotherapy in EGFR Exon 20 Insertion+ NSCLC

Nicolas Girard, MD, PhD, discusses primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.
....

Nicolas Girard , Institut Curie , Versailles Saint Quentin University , Curie Montsouris Thorax Institute , Respiratory Medicine , Onclive Tv , Versailles Saint Quentin University , Papillon Trial ,

First-Line Amivantamab Plus Lazertinib Meets PFS End Point in EGFR+ NSCLC

First-line treatment with the combination of amivantamab and lazertinib resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared with osimertinib in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations. ....

United States , Alexander Spira , Peter Lebowitz , Virginia Cancer Specialists Research Institute , Lung Cancer , Dvanced Or Metastatic Non Small Cell Lung Cancer , Phase 3 Mariposa Trial ,

Amivantamab/Chemotherapy ± Lazertinib Improves PFS in Pretreated EGFR+ NSCLC

Amivantamab-vmjw plus carboplatin and pemetrexed, administered with or without lazertinib, significantly improved progression-free survival vs chemotherapy alone in patients with locally advanced or metastatic non–small cell lung cancer with EGFR exon 19 deletions or L858R substitutions after progression on or after osimertinib. ....

Peter Lebowitz , Janssen Research Development , Janssen Research , Small Cell Lung Cancer , Lung Cancer , Janssen Research Amp Development , Egfr Nsclc , Egfr Exon 19 Deletions Or L858r Substitution , Non Small Cell Lung Cancer , Phase 3 Mariposa 2 Trial Nct04988295 ,

Choosing Treatments for Patients with NSCLC with Uncommon EGFR Mutations

Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations. ....

Julier Brahmer , Biomarker Testing , Targeted Therapies , Non Small Cell Lung Cancer , Egfr Mutations , Exon 20 Insertion Mutations ,